{"commentary":{"count":224,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":84,"youtube":81,"podcast":51,"x_video":8},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05113251\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05113251","nct_id":"NCT05113251","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05113251. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Trastuzumab deruxtecan","label":"Arm A","type":"EXPERIMENTAL"},{"description":"T-DXd, followed by THP","label":"Arm B","type":"EXPERIMENTAL"},{"description":"doxorubicin and cyclophosphamide, followed by THP","label":"Arm C","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-04-30","type":"ESTIMATED"},"conditions":["Breast Neoplasms","Breast Cancer","HER2-positive Early Breast Cancer"],"enrollment":{"count":927,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Trastuzumab Deruxtecan","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Trastuzumab","type":"DRUG"},{"name":"Pertuzumab","type":"DRUG"},{"name":"Doxorubicin","type":"DRUG"},{"name":"cyclophosphamide","type":"DRUG"}],"last_update":"2026-08-11","lead_sponsor":"AstraZeneca","official_title":"A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-03-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Rate of Pathologic Complete Response (pCR).","timeFrame":"Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025)"}],"references":[],"start_date":{"date":"2021-10-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05113251"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05113251"}